A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

NCT00135408 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Ipilimumab+ Placebo
DRUG: Ipilimumab+ Budesonide

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]